OGN

+ Watchlist + Portfolio

Organon & Co.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.71
52-Week Range: $5.69 – $13.79
Market Cap: $3.60B
P/E (TTM): 17.59
EPS (TTM): 0.78
Dividend Yield: 0.58%

Advanced Metrics

Price/Book: 3.58
PEG Ratio: —
Return on Equity: 24.04%
Return on Assets: 5.67%
Gross Margin: 53.40%
Operating Margin: 20.73%
Profit Margin: 3.41%
Current Ratio: 1.95
Debt/Equity: 8.50
Total Debt: $8.55B
Free Cash Flow: $490.75M
Revenue Growth: -2.30%
Earnings Growth: -28.30%
Enterprise Value: $11.02B

OGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.17B	$6.26B	$6.40B	$6.22B
Cost of Revenue	$2.29B	$2.52B	$2.69B	$2.90B
Gross Profit	$3.88B	$3.75B	$3.71B	$3.31B
Research & Development	$471.00M	$528.00M	$469.00M	$366.00M
Selling, General & Admin	$1.70B	$1.89B	$1.76B	$1.72B
Operating Expenses	$2.17B	$2.42B	$2.23B	$2.09B
Operating Income	$1.71B	$1.33B	$1.49B	$1.23B
EBITDA	$1.76B	$1.44B	$1.60B	$1.29B
Pretax Income	$1.12B	$673.00M	$807.00M	$425.00M
Income Tax	$205.00M	-$350.00M	-$57.00M	$238.00M
Net Income	$917.00M	$1.02B	$864.00M	$187.00M
Diluted EPS	3.59	3.99	3.33	0.72
Diluted Shares	255.17M	256.27M	259.15M	260.76M

OGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$706.00M	$693.00M	$675.00M	$574.00M
Receivables	$1.48B	$1.74B	$1.36B	$1.33B
Inventory	$1.00B	$1.31B	$1.32B	$1.41B
Current Assets	$3.93B	$4.51B	$4.35B	$4.35B
Total Assets	$10.96B	$12.06B	$13.10B	$12.87B
Current Liabilities	$2.51B	$2.92B	$2.72B	$2.39B
Long-Term Debt	$8.90B	$8.75B	$8.86B	$8.63B
Total Debt	$8.91B	$8.76B	$8.88B	$8.64B
Total Liabilities	$11.85B	$12.13B	$12.63B	$12.12B
Retained Earnings	-$331.00M	$443.00M	$1.01B	$1.11B
Shareholders' Equity	-$892.00M	-$70.00M	$472.00M	$752.00M
Working Capital	$1.42B	$1.59B	$1.63B	$1.96B
Net Debt	$8.21B	$8.07B	$8.21B	$8.07B

OGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$858.00M	$799.00M	$939.00M	$700.00M
Capital Expenditure	-$427.00M	-$261.00M	-$351.00M	-$316.00M
Free Cash Flow	$431.00M	$538.00M	$588.00M	$384.00M
Depreciation & Amortisation	$212.00M	$236.00M	$277.00M	$361.00M
Stock-Based Compensation	$75.00M	$101.00M	$105.00M	$77.00M
Investing Cash Flow	-$420.00M	-$260.00M	-$513.00M	-$390.00M
Financing Cash Flow	-$433.00M	-$569.00M	-$368.00M	-$561.00M
Dividends Paid	-$290.00M	-$294.00M	-$297.00M	-$88.00M
Net Change in Cash	$5.00M	-$30.00M	$58.00M	-$251.00M

OGN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.59B	$1.60B	$1.51B	$1.46B	$1.56B
Cost of Revenue	$720.00M	$745.00M	$766.00M	$677.00M	$711.00M
Gross Profit	$874.00M	$857.00M	$741.00M	$783.00M	$847.00M
Research & Development	$95.00M	$84.00M	$91.00M	$93.00M	$90.00M
Selling, General & Admin	$453.00M	$415.00M	$433.00M	$424.00M	$434.00M
Operating Expenses	$548.00M	$499.00M	$524.00M	$517.00M	$524.00M
Operating Income	$326.00M	$358.00M	$217.00M	$266.00M	$323.00M
EBITDA	$449.00M	$463.00M	$69.00M	$410.00M	$371.00M
Pretax Income	$229.00M	$243.00M	-$148.00M	$213.00M	$183.00M
Income Tax	$84.00M	$83.00M	$57.00M	$67.00M	$75.00M
Net Income	$145.00M	$160.00M	-$205.00M	$146.00M	$108.00M
Diluted EPS	0.56	0.61	-0.79	0.55	0.40
Diluted Shares	260.16M	260.65M	260.17M	262.90M	270.45M

OGN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$599.00M	$672.00M	$574.00M	$1.12B	$1.13B
Receivables	$1.48B	$1.48B	$1.33B	$1.38B	$1.49B
Inventory	$1.45B	$1.49B	$1.41B	$1.37B	$1.35B
Current Assets	$4.62B	$4.70B	$4.35B	$4.93B	$5.11B
Total Assets	$13.50B	$13.55B	$12.87B	$13.00B	$13.18B
Current Liabilities	$2.80B	$2.68B	$2.39B	$2.50B	$2.62B
Long-Term Debt	$8.78B	$8.78B	$8.63B	$8.55B	$8.48B
Total Debt	$8.90B	$8.83B	$8.64B	$8.57B	$8.55B
Total Liabilities	$12.77B	$12.65B	$12.12B	$12.09B	$12.17B
Retained Earnings	$1.16B	$1.32B	$1.11B	$1.25B	$1.35B
Shareholders' Equity	$733.00M	$906.00M	$752.00M	$903.00M	$1.01B
Working Capital	$1.82B	$2.02B	$1.96B	$2.43B	$2.50B
Net Debt	$8.30B	$8.16B	$8.07B	$7.45B	$7.42B

OGN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$220.00M	$264.00M	$141.00M	$225.00M	$107.00M
Capital Expenditure	-$39.00M	-$115.00M	-$65.00M	-$47.00M	-$76.00M
Free Cash Flow	$181.00M	$149.00M	$76.00M	$178.00M	$31.00M
Depreciation & Amortisation	$89.00M	$92.00M	$96.00M	$86.00M	$80.00M
Stock-Based Compensation	$22.00M	$24.00M	$7.00M	$19.00M	$25.00M
Investing Cash Flow	-$38.00M	-$115.00M	-$65.00M	$386.00M	-$76.00M
Financing Cash Flow	-$223.00M	-$76.00M	-$187.00M	-$38.00M	-$12.00M
Dividends Paid	-$10.00M	-$3.00M	-$4.00M	-$5.00M	-$6.00M
Net Change in Cash	-$41.00M	$73.00M	-$111.00M	$573.00M	$19.00M

Market Snapshot

About

Organon & Co. is a global pharmaceutical company focused on women's health and biosimilars. Spun off from Merck in 2021, the company offers products across reproductive health, contraception, fertility, menopause, and established brands in biosimilars and other therapeutic areas.